Viagra Showed Promise for Blast Brain Injuries in Rats
A drug best known for treating erectile dysfunction may offer a surprising lead in the fight against blast-related brain injuries. Researchers found that sildenafil improved several brain abnormalities in rats, with benefits still appearing when treatment began eight weeks after exposure.
U.S. Marine Corps photos by Gunnery Sgt. Rome M. Lazarus/Released)
The findings could matter for military personnel who experience repeated blasts during combat, weapons training and breaching operations. But there is a major caveat: the study was conducted in rats, not humans.
Researchers published the study in Neurotherapeutics, examining how repeated mild blast exposure affected brain function and whether sildenafil could reverse some of the damage. The team exposed male rats to two blast waves 24 hours apart, then tested treatment started either shortly after injury or eight weeks later.
Gear Spotlight- What Our Readers Are Picking Up
The results pointed to problems extending beyond the immediate impact of a blast. Repeated exposure disrupted mitochondrial function, altered the brain’s energy metabolism and affected the tiny blood vessels that help supply brain tissue. The researchers also observed anxiety-like behavior shortly after exposure and persistent fear-related behavior months later.
Sildenafil, which is sold under the brand name Viagra and also used for other medical conditions, improved several of these abnormalities in the animal models. Researchers reported improvements in mitochondrial energy production, changes in molecular pathways linked to cellular energy and partial normalization of anxiety-like behavior. At the 20-week assessment, treated animals also showed improved fear extinction, a process involved in learning that a previously threatening cue is no longer dangerous.
The most striking detail was the delayed-treatment window. Researchers began one treatment regimen eight weeks after the blast exposure and still observed benefits. That raises a question worth investigating: could some long-lasting effects of blast injury remain treatable well after the initial event? The study does not establish that the same result would occur in people.
The issue is particularly relevant to military communities, where repeated low-level blast exposure can occur during training as well as operations. Brain injuries may not always involve obvious external wounds, and some service members experience persistent symptoms after exposure. The researchers note that there are currently no FDA-approved therapies specifically for repeated mild traumatic brain injury of this type.
For now, sildenafil is not an established treatment for blast-related traumatic brain injury. Human studies would be needed to establish whether it is effective, what dose might be appropriate and whether its risks outweigh potential benefits. Patients should not use Viagra to treat a suspected brain injury without medical guidance.
The findings offer a promising research direction, not a ready-made treatment. For veterans and service members living with the long-term effects of blast exposure, however, even a potential new avenue for research could be worth watching.
Editor’s Note: This study was conducted in rats. Its findings should not be interpreted as proof that sildenafil treats traumatic brain injury in humans. More research is required before the drug can be recommended for this purpose.